FDA warns about certain compounded semaglutide products
The agency flagged safety concerns tied to compounded versions of the GLP-1 drug, a recurring pressure point for 503A and 503B pharmacies.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 17 11:04 ETSource: Managed Healthcare Executive
The wire
- 01FDA issued a warning concerning certain compounded semaglutide products, according to Managed Healthcare Executive.
- 02Compounders and telehealth prescribers dispensing semaglutide need to check whether their sourcing and formulations fall within the agency's stated concerns.
- 03The report is brief; pharmacies should read FDA's own notice for the specific products, lots and adverse events involved.
From the source
Read at managedhealthcareexecutive.comFDA Warns About Certain Compounded Semaglutide Products
